



Source: Syncromune

November 20, 2025 08:00 ET

Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an *in situ* personalized combination immunotherapy platform for solid tumor cancers, today announced that an abstract has been accepted for presentation at the Society of Urologic Oncology (SUO) 26th Annual Meeting being held December 2-5, 2025 in Phoenix, Arizona.

The abstract, titled, “Effective resolution of bone metastases in patients with metastatic prostate cancer using SYNC-T Therapy SV-102,” was selected as one of the meeting’s “Top 30” submissions. This distinction recognizes Syncromune’s work as among the highest scoring abstracts of the year. As an honoree, the research will be featured in the SUO Top Abstract Tour which showcases exemplary contributions advancing the field of urologic oncology.

The data will be presented digitally as an electronic poster and highlights findings from the now-concluded Phase 1 study of SYNC-T Therapy SV-102 in metastatic prostate cancer, with a focus on radiographic resolution of bone metastases observed in patients who achieved complete responses. These results, presented alongside broader efficacy and safety data, underscore the potential of SYNC-T to address one of the most significant drivers of morbidity and mortality in advanced prostate cancer.

Presentation details:

Presenter: Gerald Andriole, M.D.

Title: Poster 175: Effective resolution of bone metastases in patients with metastatic prostate cancer using SYNC-T Therapy SV-102

Date/Time: Top 30 Abstract Tour, Dec. 4, 2025, 4:30-5:30 PM MDT

For more information about Syncromune®, Inc. please visit www.syncromune.com.

About Syncromune® and SYNC-T™ Therapy

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class platform immunotherapy designed to address major unmet medical needs and treatment challenges of incurable metastatic solid tumor cancers. SYNC-T is an *in situ* personalized cancer therapy engineered to synchronize the location of three components critical to T cell activation and an anti-tumor immune response. SYNC-T features a novel proprietary needle-like device delivery system that is optimized for combination drug/device immunotherapy. First, the system lyses a portion of a target tumor to rupture tumor cells and release patient-specific tumor antigens into the tumor microenvironment (TME) that help to activate the immune system. Next, the delivery system facilitates the infusion of our proprietary multi-target biologic drug directly into the lysed area of the tumor. This approach of location synchronization is designed to unite the three critical components of patient-specific tumor antigens, immune modulators, and our multi-target biologic drug together in the draining lymphatics where the immune system optimally functions. The combination therapy targets numerous mechanisms of cancer, promoting *in situ* immune activation while also battling immune suppression and minimizing systemic drug exposure. The goal is to educate the immune system and activate T cells that can recognize and attack cancer throughout the body and defend with immune memory. Our lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer (mCRPC), is being evaluated in the LEGION-100 U.S., multicenter, Phase 2 trial. For more information, please visit www.legion100trial.com.

This press release includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this press release or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as “plans,” “intends,” “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this press release or expressed orally in connection herewith are made only as of the date of this press release and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this press release; or (ii) the accuracy or completeness of any information contained in this press release, any other written information or oral information provided in connection herewith or any data that any of them generates. This press release was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune’s securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Some of the information contained in this press release may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.

Corporate Contact

Danielle Hobbs

EVP, Marketing & Commercial Strategy

Syncromune, Inc.
media@syncromune.com

Media Contact

Michael Tattory

LifeSci Communications

mtattory@lifescicomms.com